MX2020003844A - Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. - Google Patents
Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica.Info
- Publication number
- MX2020003844A MX2020003844A MX2020003844A MX2020003844A MX2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A MX 2020003844 A MX2020003844 A MX 2020003844A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- nervous system
- decline
- central nervous
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
La presente invención se refiere a un compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular una disminución de la plasticidad sináptica, por ejemplo, en el tratamiento de enfermedades del sistema nervioso central que afectan a procesos cognitivos tales como el aprendizaje, la percepción, la atención, el razonamiento, el lenguaje y/o la memoria, en el tratamiento de enfermedades del sistema nervioso central tales como enfermedades neurodegenerativas que incluyen la enfermedad de Parkinson, la enfermedad de Alzheimer y/o la esclerosis lateral amiotrófica, en el tratamiento de enfermedades del sistema nervioso central responsables de los trastornos del estado de ánimo, la hiperexcitabilidad, la hiperactividad y/o el estrés, y en el tratamiento de condiciones neurológicas tales como la epilepsia, dicho compuesto siendo N-acetil taurinato de magnesio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE2017/5731A BE1025644B1 (fr) | 2017-10-13 | 2017-10-13 | Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale |
PCT/EP2018/076133 WO2019072568A1 (fr) | 2017-10-13 | 2018-09-26 | Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003844A true MX2020003844A (es) | 2020-11-06 |
Family
ID=60164541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003844A MX2020003844A (es) | 2017-10-13 | 2018-09-26 | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. |
Country Status (14)
Country | Link |
---|---|
US (2) | US20200237812A1 (es) |
EP (1) | EP3694505B1 (es) |
CN (1) | CN111315373A (es) |
BE (1) | BE1025644B1 (es) |
BR (1) | BR112020007341A2 (es) |
CA (1) | CA3079410A1 (es) |
DK (1) | DK3694505T3 (es) |
ES (1) | ES2965493T3 (es) |
FI (1) | FI3694505T3 (es) |
MX (1) | MX2020003844A (es) |
PL (1) | PL3694505T3 (es) |
PT (1) | PT3694505T (es) |
SI (1) | SI3694505T1 (es) |
WO (1) | WO2019072568A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021013851A (es) * | 2019-05-16 | 2022-01-07 | Synapharm Ind Synthesis | Compuesto y composicion para el uso en el tratamiento del sindrome premenstrual y/o trastorno disforico premenstrual. |
WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
IT1237435B (it) | 1989-12-14 | 1993-06-04 | Farmaco attivo nel ripristino della plasticita' neuronale. | |
FR2704391B1 (fr) * | 1993-04-27 | 1995-06-02 | Boiron | Complément nutritionnel absorbable pour faciliter l'adaptation au stress quodidien. |
US7148192B2 (en) * | 2004-01-29 | 2006-12-12 | Ebwe Pharma Ges. M.H. Nfg.Kg | Neuroprotective dietary supplement |
US20090098109A1 (en) * | 2006-01-23 | 2009-04-16 | President And Fellows Of Harvard College | Compositions and Methods For Enhancing Neuronal Plasticity and Regeneration |
US20080249178A1 (en) * | 2007-03-22 | 2008-10-09 | Guosong Liu | Magnesium compositions and uses thereof for increasing lifespan |
NZ579694A (en) * | 2007-03-22 | 2012-06-29 | Magceutics Inc | Magnesium threonate compositions and uses thereof |
US20110072525A1 (en) * | 2009-09-22 | 2011-03-24 | Effat Emamian | Compositions and methods for the treatment of psychiatric and neurological disorders |
JP2013506678A (ja) * | 2009-09-30 | 2013-02-28 | クレイトン ビーリー,ハーラン | 体重を維持した禁煙および栄養補助剤 |
FI129157B (fi) * | 2012-05-28 | 2021-08-13 | Biohit Oyj | Koostumus käytettäväksi vakavien päänsärkyjen esiintymistiheyden pienentämiseksi tai niiden vähentämiseksi |
AU2014235034A1 (en) * | 2013-03-15 | 2015-10-01 | Buck Institute For Research On Aging | Improved cognitive supplements |
EP3160459A1 (en) * | 2014-06-24 | 2017-05-03 | Dedraf Holding B.V. | New mineral composition |
-
2017
- 2017-10-13 BE BE2017/5731A patent/BE1025644B1/fr active IP Right Grant
-
2018
- 2018-09-26 WO PCT/EP2018/076133 patent/WO2019072568A1/fr unknown
- 2018-09-26 FI FIEP18773776.2T patent/FI3694505T3/fi active
- 2018-09-26 MX MX2020003844A patent/MX2020003844A/es unknown
- 2018-09-26 CA CA3079410A patent/CA3079410A1/en active Pending
- 2018-09-26 US US16/754,994 patent/US20200237812A1/en not_active Abandoned
- 2018-09-26 PL PL18773776.2T patent/PL3694505T3/pl unknown
- 2018-09-26 SI SI201831020T patent/SI3694505T1/sl unknown
- 2018-09-26 PT PT187737762T patent/PT3694505T/pt unknown
- 2018-09-26 ES ES18773776T patent/ES2965493T3/es active Active
- 2018-09-26 EP EP18773776.2A patent/EP3694505B1/fr active Active
- 2018-09-26 CN CN201880072217.XA patent/CN111315373A/zh active Pending
- 2018-09-26 DK DK18773776.2T patent/DK3694505T3/da active
- 2018-09-26 BR BR112020007341-5A patent/BR112020007341A2/pt unknown
-
2021
- 2021-09-22 US US17/482,003 patent/US20220008455A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3694505T3 (da) | 2024-01-02 |
SI3694505T1 (sl) | 2024-02-29 |
PL3694505T3 (pl) | 2024-04-02 |
WO2019072568A1 (fr) | 2019-04-18 |
CN111315373A (zh) | 2020-06-19 |
US20220008455A1 (en) | 2022-01-13 |
BE1025644A1 (fr) | 2019-05-10 |
EP3694505B1 (fr) | 2023-10-04 |
FI3694505T3 (fi) | 2023-12-20 |
US20200237812A1 (en) | 2020-07-30 |
BE1025644B1 (fr) | 2019-05-15 |
PT3694505T (pt) | 2023-12-05 |
CA3079410A1 (en) | 2019-04-18 |
ES2965493T3 (es) | 2024-04-15 |
EP3694505A1 (fr) | 2020-08-19 |
BR112020007341A2 (pt) | 2020-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
CO2018009889A2 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
BR112018068538A2 (pt) | composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno. | |
ECSP19021843A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
CO2018002822A2 (es) | Compuestos deuterados y usos de los mismos | |
DOP2016000195A (es) | Compuestos | |
BR112018003264A2 (pt) | conjugados de aldeído e usos dos mesmos | |
ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
BR112018071560A2 (pt) | compostos e métodos para tratar condições neurológicas e cardiovasculares | |
CL2019001092A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
CU20160151A7 (es) | 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
CL2020000085A1 (es) | Moduladores de nlrp3. | |
MX2020003844A (es) | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. | |
BR112017025263A2 (pt) | método para o tratamento de doença neurológica | |
CO2020002992A2 (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides | |
CL2018003113A1 (es) | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular. | |
PH12019500636A1 (en) | Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid | |
CL2018001633A1 (es) | Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos | |
WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
CU20160141A7 (es) | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular | |
MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
BR112017014226A2 (pt) | derivados de heterociclilalquina e sua utilização como moduladores de receptores mglur5 | |
CL2009000149A1 (es) | Compuestos heterociclos que incluyen un grupo ciclobutoxi sustituido ligandos del receptor h3 composicion farmaceutica que los comprende utiles para tratar enfermedades del sistema nervioso central, tales como deterioro cognitivo leve, alzheimer, trastornos de la memoria, enfermedad de parkinson, esquizofrenia y demencia. |